Advertisement

Topics

AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors

08:52 EDT 10 May 2019 | SCRIP

Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to...

      

Related Stories

 

Original Article: AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...